Advertisement


Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

2021 ASCO Annual Meeting

Advertisement

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance treatment forced the trial to close prematurely (Abstract 7003).



Related Videos

Prostate Cancer

Michael J. Morris, MD, on Prostate Cancer: LuPSMA in the Metastatic Setting

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the VISION study, which showed that lutetium-177–PSMA-617 (LuPSMA), a targeted radioligand therapy, plus standard-of-care treatment improves radiographic progression-free survival and extends overall survival compared with standard of care alone in men with metastatic castration-resistant prostate cancer (Abstract LBA4).

Gastroesophageal Cancer
Immunotherapy

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Ian Chau, MD, of Royal Marsden NHS Foundation Trust, discusses first results of the CheckMate 648 study, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival vs chemotherapy alone in patients with advanced esophageal squamous cell carcinoma. These regimens may represent potential new first-line treatment options (Abstract 4001).

Breast Cancer
Genomics/Genetics

Andrew Tutt, PhD, MBChB, on Breast Cancer: Olaparib After Chemotherapy in Germline BRCA1/2–Mutated Tumors

Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses findings from the phase III OlympiA trial, which showed that adjuvant olaparib, a PARP inhibitor, following adjuvant or neoadjuvant chemotherapy, may improve invasive disease–free survival in patients with germline BRCA-mutated and high-risk HER2-negative early breast cancer, which might lead to a new indication in this setting (Abstract LBA1).

Colorectal Cancer
Immunotherapy

Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer

Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).

Kidney Cancer

Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).

Advertisement

Advertisement




Advertisement